课题基金 / 基金详情

Biological activity of limitin and adiponectin

Biological activity of limitin and adiponectin
Limitin和脂联素的生物活性
批准号:
13671064
负责人:
ORITANI Kenji
金额:
$2.56万
依托单位:
依托单位国家:
日本
项目类别:
Grant-in-Aid for Scientific Research (C)
财政年份:
2001
资助国家:
日本
项目状态:
已结题
起止时间:
2001 至 2002

项目摘要

项目成果

ORITANI Kenji的其他基金

相似基金

相关文献

中文摘要
翻译
(1)脂联素:脂联素是脂肪细胞的主要产物之一,在长期培养的骨髓细胞中,脂联素强烈抑制B淋巴细胞的生成,但仅在基质细胞存在的情况下。在含有脂联素的基质细胞培养中,COX-2抑制剂取消了早期淋巴祖细胞对脂联素的反应。此外,COX-2活性的主要产物前列腺素E_2对纯化的造血细胞有直接的抑制作用,提示脂联素在培养中可能的作用机制。(2)利米丁:利米丁是一种干扰素样细胞因子,可增强细胞毒性T淋巴细胞的杀伤活性和MHC I类分子的表面表达。利米丁抑制稳定表达p210bcr/ABL的FDCP-1细胞的增殖。利米丁还能诱导抗EMCV、MHV和HSV的抗病毒状态。虽然利米丁的上述功能与干扰素-α相似,但抑制CFU-IL-7或CFU-MEG的集落形成需要比干扰素-α更高的浓度。利米丁不能抑制CFU-GM或BFU-E的集落形成,而干扰素-α则有抑制作用。这些数据表明,利米丁的毒性可能比其他IFN低,因此在治疗I型IFN被证明有效的疾病方面可能有独特的临床利基。在干扰素介导的骨髓抑制信号中,TYK2的阻断完全阻断了干扰素-α对CFU-IL7和CFU-MEG集落形成的抑制作用。我们正在分析Limitin和干扰素-α中TYK2下游信号的差异。免疫组织化学分析表明,Limitin蛋白是由脾和胸腺中成熟的T淋巴细胞结构性产生的。与其他IFN不同,Limitin的表达不会因病毒感染而上调。这些数据可能表明,Limitin的作用是避免病毒感染或在健康条件下消除有害细胞。
英文摘要
(1) Adiponectin: Adiponectin, one of the major products of adipocytes, strongly inhibited B lymphopoiesis in long-term bane marrow cultures, but only when stromal cells were present. Cox-2 inhibitors abrogated the response of early lymphoid progenitors to adiponectin in stromal cell containing cultures. Furthermore, prostaglandin E2, a major product of Cox-2 activity; had a direct inhibitory influence on purified hematopoietic cells, suggesting a possible mechanism of adiponectin action in culture.(2) Limitin: Limitin, an IFN-like cytokine, augmented the killer activity of cytotoxic T lymphocytes as well as the surface expression of MHC class I molecules. Limitin inhibited the proliferation of FDCP-1 cells stably transfected with p210bcr/abl. Limitin also induced antiviral state against EMCV, MHV, and HSV. Although the above functions of limitin were similar to those of IFN-α, higher concentration of limitin was required than IFN-α for the inhibition of CFU-IL7 or CFU-Meg colony formation. Limitin could not inhibit CFU-GM or BFU-E colony formation while IFN-α did. These data suggest that limitin may be less toxic than other IFNs, and therefore may have a unique clinical niche for treatment of diseases where type I IFNs have proven useful. In signals for IFN-mediated myelosuppression, the disruption of Tyk2 completely abrogated IFN-α-induced inhibition of CFU-IL7 and CFU-Meg colony formation. We are now analyzing the difference of downstream signals of Tyk2 between limitin and IFN-α.Immunohistochemical analysis revealed that the limitin protein is constitutively produced by mature T lymphocytes in spleen and thymus. Unlikely other IFNs, limitin expression was not up-regulated by virus-infection. These data may suggest that limitin acts to avoid virus-infection or to eliminate harmful cells in healthy conditions.
期刊论文(21)
专著(0)
科研奖励(0)
会议论文
Yokota T: "Paracrine regulation of fat cell formation in bone marrow cultures via adiponectin and prostaglandins"J Clin Invest. 109. 1303-1310 (2002)
Yokota T:“通过脂联素和前列腺素对骨髓培养物中脂肪细胞形成的旁分泌调节”J Clin Invest。
DOI: --
发表时间:
期刊:
影响因子: --
作者: []
通讯作者:
Yoshida H et al.: "Interaction between SHPS-1 and CD47 mediates the adhesion of human B lymphocytes to non activated endothelial cells"J Immunol. (in peess).
Yoshida H 等人:“SHPS-1 和 CD47 之间的相互作用介导人 B 淋巴细胞与非活化内皮细胞的粘附”JImmunol。
DOI: --
发表时间:
期刊:
影响因子: --
作者: []
通讯作者:
Yokota T et al.: "Paracrine regulation of fat cell formation in bone marrow cultures via adiponectin and prostaglandins."J Clin Invest. 109. 1303-1310 (2002)
Yokota T 等人:“通过脂联素和前列腺素对骨髓培养物中脂肪细胞形成进行旁分泌调节。”J Clin Invest。
DOI: --
发表时间:
期刊:
影响因子: --
作者: []
通讯作者:
Shimoda K: "Cutting edge : tyk2 is required for the induction and nuclear translocation of Daxx which regulates IFN-alpha-induced suppression of B lymphocyte formation"J Immunol. 169. 4707-4711 (2002)
Shimoda K:“最前沿:tyk2 是 Daxx 的诱导和核转位所必需的,Daxx 调节 IFN-α 诱导的 B 淋巴细胞形成抑制”JImmunol。
DOI: --
发表时间:
期刊:
影响因子: --
作者: []
通讯作者:
共 21 条
    Analysis of in vivo effects of possible immune regulatory moleculesfor artificial management of immune systems
    • 批准号:
      22591062
    • 项目类别:
      Grant-in-Aid for Scientific Research (C)
    • 资助金额:
      $2.75万
    • 财政年份:
      2010
    • 负责人:
      ORITANI Kenji
    • 依托单位:
    Development of a novel interferon with mild adverse effects
    • 批准号:
      19390264
    • 项目类别:
      Grant-in-Aid for Scientific Research (B)
    • 资助金额:
      $11.98万
    • 财政年份:
      2007
    • 负责人:
      ORITANI Kenji
    • 依托单位:
    Establishment of a novel IFN therapy with little side effects
    • 批准号:
      17390277
    • 项目类别:
      Grant-in-Aid for Scientific Research (B)
    • 资助金额:
      $9.86万
    • 财政年份:
      2005
    • 负责人:
      ORITANI Kenji
    • 依托单位:
    Difference of biological activities and signals between IFN-ζ/limitin and IFN-α
    • 批准号:
      15390300
    • 项目类别:
      Grant-in-Aid for Scientific Research (B)
    • 资助金额:
      $9.47万
    • 财政年份:
      2003
    • 负责人:
      ORITANI Kenji
    • 依托单位:
    海外基金